CBN, New Delhi Busted Illicit Drug Syndicate, Seized Large Quantity Of NDPS Drugs Worth More Than A Crore

New Delhi: In continuous crackdown on illicit drug menace, Central bureau of Narcotics, New Delhi achieved a major breakthrough and busted the clandestine illicit drug syndicate operating at M/s V K Enterprises at New Shobatia Bag Area in Prayagraj and arrested the proprietor Vipul Tiwari s/o Vinod Tiwari of the firm.

The firm was a distributor of various NDPS medicines which are meant to be disbursed under strict medical supervision. Central Bureau of Narcotics seized the following NDPS drugs:

Ketamine- 6273 Vial, Tramadol Tab- 4530 Tab, Tramadol Cap.- 113616 Cap, Tramadol Inj. – 12150 Inj Alprazolam Tab. – 136200, Diazepam Tabs- 8600, Diazepam Inj. – 1200, Clonazepam Tab.- 8500, Chlordiazepoxide Tab.- 300, Lorazepam Inj.- 3910, Nitrazepam Tab. – 4100, Codeine Phosphate tab- 150, Codeine Phosphate Syrup- 890, Etizolam Tab. 200, Clobazam Tab.- 3200, Pentazocine Inj.- 26890, Buprenorphine Inj.- 1225, Buprenorphine Patch- 12, Fentanyl Patch- 309, Fentanyl vial/inj- 2817, Medicinal Opium Pills- 220 Grams, Midazolam Vial – 325, Morphine Sulphate Inj. – 140, Morphine Sulphate Tab.- 660.

The firm was consciously indulged in diversion of NDPS medicines into the illicit drug market.

It is pertinent to mention that Fentanyl is one of the most potent medicines which is used for acute pain management and this medicine may cause casualty if it is not taken under strict medical supervision.

A case crime no. 01/24 has been registered and further investigation in the case is under progress.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’